Key Highlights

● Pfizer closed at $28.27 on 9 October 2026.

● Market data consensus target is $28.72 from 21 analysts.

● The analyst rating consensus is Buy.

● JPMorgan lifted its target from $28 to $30 on 9 October.

Pfizer (NYSE:PFE), a member of the S&P 500, ended Friday 9 October 2026 at $28.27. The consensus target sits close to the share price. Recent broker revisions have mostly been upward.

What Is the Latest Analyst Price Target?

Market data shows a consensus price target of $28.72 from 21 analysts, only about 1.6% above the $28.27 close. Its targets range from $25.00 to $35.00. The second data set, which counts 28 analysts, shows a slightly higher mean of $29.26 (about 3.5% above the price), a median of $28.50 and a range of $25 to $36.

Recent named targets, between $26 and $36, fit around both averages.

What Are Wall Street Analysts Saying?

The prevailing view is neutral. Market data records five Buy, 14 Hold and two Sell ratings, giving a Hold consensus. The second data set lists eight Strong Buy, two Buy, 16 Hold, one Sell and one Strong Sell.

Several brokers raised targets this month. JPMorgan Chase lifted its Neutral target from $28 to $30 on 9 October 2026, Cantor Fitzgerald raised its Neutral target from $27 to $28 on 8 October, and Scotiabank raised its Outperform target from $30 to $33 on 6 October. Bank of America moved its target from $27 to $29 and Jefferies raised its Buy target from $35 to $36, while DBS maintained a Buy with a $35 target. UBS held a $27 target with a Hold rating. HSBC raised its Hold target from $28 to $30 in September. Earlier in the summer, Guggenheim cut its Buy target from $35 to $31, and BMO Capital Markets cut its Outperform target from $34 to $30.

What Could Help the Stock Reach the Price Target?

Little movement is required, as the market data consensus is only about 1.6% above the latest close. The cluster of upward target revisions in early October suggests analysts have become somewhat more constructive, and higher targets of $30 to $36 from several firms indicate room for the average to rise further. Market data includes text describing a quarterly earnings beat and a dividend of $0.43 per share. Positive company updates, pipeline progress or clearer guidance could support further upgrades.

What Could Prevent the Stock Reaching the Target?

With a consensus close to the share price, the stock has little analyst-implied cushion if sentiment weakens. Hold ratings dominate, and two analysts on market data have Sell ratings. Pharmaceutical shares can be affected by clinical trial outcomes, drug pricing and regulation, patent expirations and wider market conditions. The summer target cuts from Guggenheim, BMO and Bank of America show that revisions can go in either direction.

What Should Investors Watch Next?

Investors may wish to watch whether the recent run of target increases continues after the next results, whether the shares move above the $28 to $30 band where many targets sit, and how company guidance changes analysts' estimates.

Pfizer Versus Its Analyst Targets

Pfizer closed at $28.27 on 9 October 2026, against a market data consensus target of $28.72. JPMorgan Chase lifted its Neutral target from $28 to $30 on 9 October 2026, Cantor Fitzgerald raised its Neutral target from $27 to $28 on 8 October, and Scotiabank raised its Outperform target from $30 to $33 on 6 October.